FDA approves lower-cost alternative to biotech drug Humira

By Associated Press  |  September 24, 2016

Federal regulators have approved the first alternative version of the second-best selling drug in the world, Humira, the blockbuster injection used to treat rheumatoid arthritis and other inflammatory diseases.

Lower-cost biotech drug gets thumbs up from FDA panel

By Associated Press  |  July 12, 2016

AbbVie's Humira, the second-biggest selling drug in the world, could get some cheaper competition in the U.S., after a federal panel endorsed an alternative version of the pricey medication used to treat some inflammatory diseases.

FDA decision could impact competition for Amgen

By Steven Ross Johnson  |  July 09, 2016

Amgen is bracing for yet another drug to compete with its biologic medications. An FDA advisory panel is scheduled to consider approval Wednesday of a biosimilar created by Sandoz, Novartis' generic arm. The panel will advise the FDA, which makes the final call.

Hedge fund boss pares back healthcare investments

Hedge fund boss pares back healthcare investments

By Bob Herman  |  May 21, 2016

Just three years ago, billionaire hedge fund manager Larry Robbins fought tooth and nail for Community Health Systems' $7.6 billion takeover of Health Management Associates. Now he has lost faith in that massive hospital deal—and in the healthcare sector more broadly.

Rheumatoid arthritis drug prices on the rise

By Adam Rubenfire  |  April 01, 2016

Rheumatoid arthritis drug prices have skyrocketed over the past three years, despite little to no change in composition, experts and insurers say.

Senator scrutinizes pharma links on government pain panel

Senator scrutinizes pharma links on government pain panel

By Associated Press  |  February 08, 2016

Sen. Ron Wyden says he has "a number of concerns" about how panelists were selected and screened for an advisory panel on pain issues that includes government experts, outside academics and patient advocates.

Humira sales boost AbbVie's fourth-quarter profit

By Associated Press  |  January 29, 2016

Cost-cutting also helped AbbVie in the quarter. The North Chicago, Ill., company's selling, general and administrative expenses dropped 48% to $1.74 billion.

Pfizer-Allergan deal could reduce biosimilar cost savings

Pfizer-Allergan deal could reduce biosimilar cost savings

By Steven Ross Johnson  |  December 05, 2015

Pfizer's $160 billion deal to acquire Irish drugmaker Allergan got a lot of attention for the tax advantages Pfizer would enjoy from moving its New Jersey headquarters overseas to Dublin. There wasn't much talk, though, about how much the deal would expand Pfizer's footprint in biosimilars.


Subscribe and SAVE 50%

View our best offer
Subscribe to Print